Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease ...
From diversity in Indonesia to history in Greece and food in France: People in 25 countries share what makes them proud, in their own words. Fresh data delivered Saturday mornings Thank you for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results